Glycine modulators in schizophrenia

Current Opinion in Investigational Drugs

Volumn 3, Issue 7, 2002, Pages 1067-1072

  Javitt, Daniel C ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Glycine; NMDA; Schizophrenia

Indexed keywords

1 AMINOCYCLOPROPANECARBOXYLIC ACID; AMINO ACID TRANSPORTER; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; CYCLOSERINE; DEXTRO ALANINE; DEXTRO SERINE; GLYCINE; GLYCINE DERIVATIVE; GLYCINE RECEPTOR AGONIST; GLYCINE TRANSPORT INHIBITOR; N [3 (4' FLUOROPHENYL) 3 (4' PHENYLPHENOXY)PROPYL]SARCOSINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; OLANZAPINE; ORG 24598; RISPERIDONE; SARCOSINE; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG;

BLOOD BRAIN BARRIER; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DOSE RESPONSE; DRUG METABOLISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; EXPERIMENTAL MODEL; HUMAN; NEGATIVE SYNDROME; NONHUMAN; REVIEW; SCHIZOPHRENIA; SIDE EFFECT;

ANIMALS; GLYCINE; HUMANS; RECEPTORS, GLYCINE; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA;

EID: 0036667177     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull (1987) 13:261-276.
2. Andreasen NC, Arndt S, Miller D, Flaum M, Nopoulos P: Correlational studies of the Scale for the Assessment of Negative Symptoms and the Scale for the Assessment of Positive Symptoms: An overview and update. Psychopathology (1995) 28:7-17.
3. Javitt DC: Negative schizophrenic symptomatology and the phencyclidine (PCP) model of schizophrenia. Hillside J Clin Psychiatry (1987) 9:12-35.
4. Javitt DC, Zukin SR: Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry (1991) 148:1301-1308. Comprehensive review of the PCP/NMDA model of schizophrenia.
5. Newcomer JW, Farber NB, Jevtovic-Todorovic V, Selke G, Melson AK, Hershey T, Craft S, Olney JW: Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology (1999) 20:106-118. Comprehensive review of the NMDA hypofunction model of schizophrenia.
6. Goff DC, Coyle JT: The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry (2001) 158:1367-1377. Comprehensive review of the glutamatergic theories of schizophrenia.
7. Luby ED, Gottlieb JS, Cohen BD, Fosenbaum G, Domino EF: Model psychoses and schizophrenia. Am J Psychiatry (1962) 119:61-67.
8. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS: Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry (1994) 51:199-214.
9. Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D, Breier A: NMDA receptor function and human cognition: The effects of ketamine in healthy volunteers. Neuropsychopharmacology (1996) 14:301-307.
10. Lahti AC, Koffel B, LaPorte D, Tamminga CA: Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology (1995) 13:9-19.
11. Malhotra AK, Pinals DA, Adler CM, Elman I, Clifton A, Pickar D, Breier A: Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology (1997) 17:141-150.
12. Adler CM, Malhotra AK, Elman I, Goldberg T, Egan M, Pickar D, Breier A: Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am J Psychiatry (1999) 156:1646-1649.
13. Umbricht D, Schmid L, Koller R, Vollenweider FX, Hell D, Javitt DC: Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: Implications for models of cognitive deficits in schizophrenia. Arch Gen Psychiatry (2000) 57:1139-1147.
14. Hetem LA, Danion JM, Diemunsch P, Brandt C: Effect of a subanesthetic dose of ketamine on memory and conscious awareness in healthy volunteers. Psychopharmacology (2000) 152:283-288.
15. Radant AD, Bowdle TA, Cowley DS, Kharasch ED, Roy-Byrne PP: Does ketamine-mediated N-methyl-D-aspartate receptor antagonism cause schizophrenia-like oculomotor abnormalities? Neuropsychopharmacology (1998) 19:434-444.
16. Kegeles LS, Abi-Dargham A, Zea-Ponce Y, Rodenhiser-Hill J, Mann JJ, Van Heertum RL, Cooper TB, Carlsson A, Laruelle M: Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: Implications for schizophrenia. Biol Psychiatry (2000) 48:627-640.
17. Balla A, Koneru R, Smiley J, Sershen H, Javitt DC: Continuous phencyclidine treatment induces schizophrenia-like hyperreactivity of striatal dopamine release. Neuropsychopharmacology (2001) 25:157-164.
18. Balla A, Hashim A, Burch S, Javitt DC, Lajtha A, Sershen H: Phencyclidine-induced dysregulation of dopamine response to amphetamine in prefrontal cortex and striatum. Neurochem Res (2001) 26:1001-1006.
19. Hashimoto A, Nishikawa T, Hayashi T, Fujii N, Harada K, Oka T, Takahashi K: The presence of free D-serine in rat brain. FEBS Lett (1992) 296:33-36.
20. Matsui T, Sekiguchi M, Hashimoto A, Tomita V, Nishikawa T, Wada K: Functional comparison of D-serine and glycine in rodents: The effect on cloned NMDA receptors and the extracellular concentration. J Neurochem (1995) 65:454-458.
21. Dunlop DS, Neidle A: The origin and turnover of D-serine in brain. Biochem Biophys Res Commun (1997) 235:26-30.
22. Snyder SH, Kim PM: D-amino acids as putative neurotransmitters: Focus on D-serine. Neurochem Res (2000) 25:553-560.
23. D'Souza DC, Gil R, Cassello K, Morrissey K, Abi-Saab D, White J, Sturwold R, Bennett A, Karper LP, Zuzarte E, Charney DS, Krystal JH: IV glycine and oral D-cycloserine effects on plasma and CSF amino acids in healthy humans. Biol Psychiatry (2000) 47: 450-462.
24. Ganote CE, Peterson DR, Carone FA: The nature of D-serine-induced nephrotoxicity. Am J Pathol (1974) 77:269-282.
25. Carone FA, Ganote CE: D-serine nephrotoxocity. The nature of proteinuria, glucosuria, and aminoaciduria in acute tubular necrosis. Arch Pathol (1975) 99:658-662.
26. Hood WF, Compton,RP,Monahan JB: D-cycloserine: A ligand for the N-methyl-D-aspartate coupled glycine receptor has partial agonist characteristics. Neurosci Lett (1989) 98:91-95.
27. Watson GB, Bolanowski MA, Baganoff MP, Deppeler CL, Lanthorn TH: D-cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in Xenopus oocytes. Brain Res (1990) 510:158-160.
28. Sheinin A, Shavit S, Benveniste M: Subunit specificity and mechanism of action of NMDA partial agonist D-cycloserine. Neuropharmacology (2001) 41:151-158.
29. Smith KE, Borden LA, Hartig PR, Branchek T, Weinshank RL: Cloning and expression of a glycine transporter reveal colocalization with NMDA receptors. Neuron (1992) 8:927-935.
30. Supplisson S, Bergman C: Control of NMDA receptor activation by a glycine transporter co-expressed in Xenopus oocytes. J Neurosci (1997) 17:4580-4590.
31. Berger AJ, Dieudonne S, Ascher P: Glycine uptake governs glycine site occupancy at NMDA receptors of excitatory synapses. J Neurophysiol (1998) 80:3336-3340.
32. Roux MJ, Supplisson S: Neuronal and glial glycine transporters have different stoichiometries. Neuron (2000) 25:373-383. Detailed description of the role played by GLYT1 transporters in NMDA regulation.
33. Toth E, Lajtha A: Antagonism of phenycyclidine-induced hyperactivity by glycine in mice. Neurochem Res (1986) 11:393-400.
34. Toth E, Weiss B, Banay-Schwartz M, Lajtha A: Effect of glycine derivatives on behavioral changes induced by 3-mercaptopropionic acid or phencyclidine in mice. Res Comm Psychol Psychiat Behav (1986) 11:1-9.
35. Javitt DC, Balla A, Sershen H, Lajtha A: A.E. Bennett Research Award. Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors. Biol Psychiatry (1999) 45:668-679.
36. Tanii Y, Nishikawa T, Hashimoto A, Takahashi K: Stereoselective inhibition by D- and L-alanine of phencyclidine-induced locomotor stimulation in the rat. Brain Res (1991) 563:281-284.
37. Tanii Y, Nishikawa T, Hashimoto,A,Takahashi K: Stereoselective antagonism by enantiomers of alanine and serine of phencyclidine-induced hyperactivity, stereotypy and ataxia in the rat. J Pharmacol Exp Ther (1994) 269:1040-1048.
38. Contreras PC: D-serine antagonized phencyclidine- and MK-801-induced stereotyped behavior and ataxia. Neuropharmacology (1990) 29:291-293.
39. Kato K, Shishido T, Ono M, Shishido K, Kobayashi M, Niwa S: Glycine reduces novelty- and methamphetamine-induced locomotor activity in neonatal ventral hippocampal damaged rats. Neuropsychopharmacology (2001) 24:330-332.
40. Shoham S, Javitt DC, Heresco-Levy U: High dose glycine nutrition affects glial cell morphology in rat hippocampus and cerebellum. Int J Neuropsychopharmacol (1999) 2:35-40.
41. Shoham S, Javitt DC, Heresco-Levy U: Chronic high-dose glycine nutrition: Effects on rat brain cell morphology. Biol Psychiatry (2001) 49:876-885.
42. Waziri R: Glycine therapy of schizophrenia (Letter). Biol Psychiatry (1988) 23:210-221.
43. Javitt DC, Zylberman I, Zuki SR, Heresco-Levy U, Lindenmayer JP: Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry (1994) 151:1234-1236.
44. Heresco-Levy U, Javitt DC, Irmilov M, Mordel C, Horowitz A, Kelly D: Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry (1996) 169:610-617.
45. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M: Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry (1999) 56:29-36. Clinical trial demonstrating the effectiveness of glycine (0.8 g/kg/day) in the treatment of persistent negative and cognitive symptoms of schizophrenia.
46. Kirkpatrick B, Buchanan RW, McKenney PD, Alphs LD, Carpenter WT Jr: The schedule for the deficit syndrome: An instrument for research in schizophrenia. Psychiatry Res (1989) 30:119-124.
47. Javitt DC, Silipo G, Cienfuegos A, Shelley AM, Bark N, Park M, Lindenmayer JP, Suckow R, Zukin SR: Adjunctive high-dose glycine in the treatment of schizophrenia. Int J Neuropsychopharmacol (2001) 4:385-391. Clinical trial demonstrating the effectiveness of glycine (0.8 g/kg/day) in the treatment of persistent negative and cognitive symptoms of schizophrenia.
48. 3H]MK-801 with multiple states of the N-methyl-D- aspartate receptor complex of rat brain. Proc Natl Acad Sci USA (1989) 86:740-744.
49. D'Souza DC, Charney D, Krystal J: Glycine site agonists of the NMDA receptor: A review. CNS Drug Rev (1995) 1:227-260. Comprehensive review of early clinical trials with glycine and D-cycloserine; rationale for treatment with D-serine and D-alanine.
50. Tsai G, Yang P, Chung LC, Lange N, Coyle JT: D-Serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry (1998) 44:1081-1089. Clinical trial showing the effectiveness of D-serine (30 mg/kg/day) in the treatment of persistent negative and cognitive symptoms of schizophrenia.
51. Goff DC, Tsai G, Levitt J, Amico E, Manoach D, Schoenfeld DA, Hayden DL, McCarley R, Coyle JT: A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry (1999) 56:21-27. Clinical trial demonstrating the effectiveness of D-cycloserine (50 mg/day) in the treatment of persistent negative and cognitive symptoms of schizophrenia.
52. Heresco-Levy U, Javitt DC, Ermilov M, Silipo G, Shimoni J: Double-blind, placebo-controlled, crossover trial of D-cycloserine adjuvant therapy for treatment-resistant schizophrenia. Int J Neuropsychopharmacol (1998) 1:131-136. Clinical trial demonstrating the effectiveness of D-cycloserine (50 mg/day) in the treatment of persistent negative and cognitive symptoms of schizophrenia.
53. Van Berckel BN, Hijman R, Van Der Linden JA, Westenberg HG, Van Ree JM, Kahn RS: Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients. Biol Psychiatry (1996) 40:1298-1300.
54. Cascella NG, Macciardi F, Cavallini C, Smeraldi E: D-Cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: An open-label study. J Neural Transmission (1994) 95: 105-111.
55. Goff DC, Tsai G, Manoach DS, Coyle JT: Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry (1995) 152:1213-1215.
56. Van Berckel BN, Evenblij CN, Van Loon BJ, Maas MF, Van Der Geld MA, Wynne HJ, Van Ree JM, Kahn RS: D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: A double-blind, parallel, placebo-controlled study. Neuropsychopharmacology (1999) 21:203-210.
57. Javitt DC, Heresco-Levy U: Comparative effects of glycine and D-cycloserine on persistent negative and cognitive symptoms of schizophrenia: A retrospective analysis. Schizophr Res (2002) manuscript submitted.
58. Potkin SG, Jin Y, Bunney BG, Costa J, Gulasekaram B: Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. Am J Psychiatry (1999) 156:145-147.
59. Evins AE, Fitzgerald SM, Wine L, Rosselli R, Goff DC: Placebo-controlled trial of glycine added to clozapine in schizophrenia. Am J Psychiatry (2000) 157:826-828.
60. Tsai GE, Yang P, Chung LC, Tsai IC, Tsai CW, Coyle JT: D-serine added to clozapine for the treatment of schizophrenia. Am J Psychiatry (1999) 156:1822-1825.
61. Goff DC, Tsai G, Manoach DS, Flood J, Darby D, Coyle JT: D-cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry (1996) 153:1628-1630.
62. Heresco-Levy U, Ermilov M, Shimoni J, Shapira B, Silipo G, Javitt DC: Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. Am J Psychiatry (2002) 159:480-482. Clinical trial demonstrating the effectiveness of D-cycloserine (50 mg/day) in the treatment of persistent negative and cognitive symptoms of schizophrenia.
63. Heresco-Levy U, Javitt DC, Ermilov M, Lichtenberg P, Bar G: High dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Arch Gen Psychiatry (2002) manuscript submitted.
64. Arvanov VL, Liang X, Schwartz J, Grossman S, Wang RY: Clozapine and haloperidol modulate N-methyl-D-aspartate- and non-N-methyl-D-aspartate receptor-mediated neutrotransmission in rat prefrontal cortical neurons in vitro. J Pharmacol Exp Ther (1997) 283:226-234.
65. Arvanov VL, Wang RY: Clozapine, but not haloperidol, prevents the functional hyperactivity of N-methyl-D-aspartate receptors in rats cortical neurons induced by subchronic administration of phencyclidine. J Pharmacol Exp Ther (1999) 289:1000-1006.
66. Javitt DC, Sershen H, Hashim A, Lajtha A: Reversal of phencyclidine-induced hyperactivity by glycine and the glycine uptake inhibitor glycyldodecylamide. Neuropsychopharmacol (1997) 17:202-204.
67. Javitt DC, Frusciante M: Glycyldodecylamide, a phencyclidine behavioral antagonist, blocks cortical glycine uptake: Implications for schizophrenia and substance abuse. Psychopharmacol (1997) 129:96-98.
68. 3H]glycine release in the rat brain. Neurochem Res (2001) 26:915-923.
69. Javitt DC, Sershen H, Hashim A, Lajtha A: Inhibition of striatal dopamine release by glycine and glycyldodecylamide. Brain Res Bull (2000) 52:213-216.
70. Atkinson BN, Bell SC, De Vivo M, Kowalski LR, Lechner SM, Ognyanov VI, Tham CS, Tsai C, Jia J, Ashton D, Klitenick MA: ALX 5407: A potent, selective inhibitor of the hGlyT1 glycine transporter. Mol Pharmacol (2001) 60:1414-1420.
71. Aubrey KR, Vanderberg RJ: N-[3-(4′-fluorophenyl)-3-(4′-phenylphenoxy)propyl]sarcosine (NFPS) is a selective persistent inhibitor of glycine transport. Br J Pharmacol (2001) 134:1429-1436.
72. Herdon HJ, Godfrey FM, Brown AM, Coulton S, Evans JR, Caims WJ: Pharmacological assessment of the role of the glycine transporter GlyT-1 in mediating high-affinity glycine uptake by rat cerebral cortex and cerebellum synaptosomes. Neuropharmacology (2001) 41:88-96.
73. Bergeron R, Meyer TM, Coyle JT, Greene RW: Modulaton methyl-D-aspartate receptor function by glycine transport. Proc Natl Acad Sci USA (1998) 95:15730-15734.
74. Klitenick MA, Atkinson BN, Baker DA, Bakker M, Bell SC, Borghys H, Caron MG, Ceuster M, De Coster R, DeVivo M, DelVicchio RA, Draper S, Egle I, Frey J, Calnetdinov RR, Hopper AT, Javitt DC, Kalivas PW, Kril Y, Langlois X, Lechner SM, Lewis BL, Lipska BK, Megens A, O'Brien A, O'Connor WT, O'Donnell P, Sershen SE, Shen H, Tehim A, Tham CS, Turchin PI, Van Beljsterveldt L, Van Lommen G, Ashton D: Development and characterization of GlyT1-selective glycine reuptake inhibitors. American College of Neuropsychopharmacology 40th Annual Meeting (2001).
75. Brown A, Carlyle I, Clark J, Hamilton W, Gibson S, McGarry G, McEachen S, Rae D, Thom S, Walker G: Discovery and SAR of ORG 24598 - A selective glycine uptake inhibitor. Bioorg Med Chem Lett (2001) 11:2007-2009.
76. Glytech Inc (Javitt DC, Zukin SR:): Treatment of negative and cognitive symptoms of schizophrenia with glycine and its precursors. US-05854286 (1998).
77. Glytech Inc (Javitt DC): Treatment of negative and cognitive symptoms of schizophrenia with D-serine. US-06162827 (2000).
78. Glytech Inc (Javitt DC): Glycine substitutes and precursors for treating a psychosis. US-06355681 (2002).
79. The General Hospital Corporation (Tsai G, Coyle J): Methods for treating neuropsychiatric disorders. US-06228875 (2001).
80. GD Searle & Co (Cordi AA): Cordi AA US-05187171 (1993).
81. United States of America Health & Human Services (Skolnick P, Lewin A, Marvizon J.-C, Monn J, Rice K): Partial agonists of the strychnine insensitive glycine modulatory site of the N-methyl-D-aspartate receptor complex as neuropsychopharmacological agents. US-06017957 (2000).
82. Glytech Inc (Javitt DC): Treatment of negative and cognitive symptoms of schizophrenia with glycine uptake antagonists. US-05837730 (1998).